ES2355680T3 - Reducción del sobrepeso o de la obesidad. - Google Patents

Reducción del sobrepeso o de la obesidad. Download PDF

Info

Publication number: ES2355680T3
Authority: ES; Spain
Prior art keywords: bgp; body weight; obesity; pharmaceutical composition; weight gain
Prior art date: 2006-11-02
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Active

Application number

ES07766498T

Other languages

English (en)

Spanish (es)

Inventor

Péter LITERATI NAGY

Zoltán SZILVASSY

Kálmán TORY

László VIGH

Kálmán TAKACS

József MANDL

Balázs SÜMEGI

Sándor BERNATH

Attila Kolonics

Gábor BALOGH

János EGRI

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

N-Gene Research Laboratories Inc

Original Assignee

N-Gene Research Laboratories Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-11-02

Filing date

2007-07-23

Publication date

2011-03-30

2007-07-23 Application filed by N-Gene Research Laboratories Inc filed Critical N-Gene Research Laboratories Inc

2011-03-30 Application granted granted Critical

2011-03-30 Publication of ES2355680T3 publication Critical patent/ES2355680T3/es

Status Active legal-status Critical Current

2027-07-23 Anticipated expiration legal-status Critical

Links

208000008589 Obesity Diseases 0.000 title claims abstract description 19
235000020824 obesity Nutrition 0.000 title claims abstract description 19
206010033307 Overweight Diseases 0.000 title claims abstract description 14
230000009467 reduction Effects 0.000 title claims abstract description 12
239000008194 pharmaceutical composition Substances 0.000 claims abstract description 23
239000002253 acid Substances 0.000 claims abstract description 16
150000003839 salts Chemical class 0.000 claims abstract description 9
SFZULDYEOVSIKM-UHFFFAOYSA-N chembl321317 Chemical compound C1=CC(C(=N)NO)=CC=C1C1=CC=C(C=2C=CC(=CC=2)C(=N)NO)O1 SFZULDYEOVSIKM-UHFFFAOYSA-N 0.000 claims abstract description 7
230000002265 prevention Effects 0.000 claims abstract description 6
LEAWDHURBAHMCQ-UHFFFAOYSA-N (2-hydroxy-3-piperidin-1-ylpropyl) pyridine-3-carboxylate Chemical compound C1CCCCN1CC(O)COC(=O)C1=CC=CN=C1 LEAWDHURBAHMCQ-UHFFFAOYSA-N 0.000 claims abstract description 3
238000002360 preparation method Methods 0.000 claims abstract description 3
230000037396 body weight Effects 0.000 claims description 34
-1 3-piperidino-2-hydroxy-1-propyl Chemical group 0.000 claims description 7
230000002159 abnormal effect Effects 0.000 claims description 7
206010000188 Abnormal weight gain Diseases 0.000 abstract description 3
ISGGVCWFTPTHIX-UHFFFAOYSA-N n'-(2-hydroxy-3-piperidin-1-ylpropoxy)pyridine-3-carboximidamide;dihydrochloride Chemical compound Cl.Cl.C1CCCCN1CC(O)CONC(=N)C1=CC=CN=C1 ISGGVCWFTPTHIX-UHFFFAOYSA-N 0.000 description 55
208000021017 Weight Gain Diseases 0.000 description 26
235000019786 weight gain Nutrition 0.000 description 26
238000011282 treatment Methods 0.000 description 22
KVWDHTXUZHCGIO-UHFFFAOYSA-N olanzapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2NC2=C1C=C(C)S2 KVWDHTXUZHCGIO-UHFFFAOYSA-N 0.000 description 20
241001465754 Metazoa Species 0.000 description 19
229960005017 olanzapine Drugs 0.000 description 19
230000000694 effects Effects 0.000 description 17
241000699670 Mus sp. Species 0.000 description 10
RAPZEAPATHNIPO-UHFFFAOYSA-N risperidone Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCCC4=NC=3C)=NOC2=C1 RAPZEAPATHNIPO-UHFFFAOYSA-N 0.000 description 9
YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical compound C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 description 8
239000004480 active ingredient Substances 0.000 description 8
235000005911 diet Nutrition 0.000 description 8
229960001534 risperidone Drugs 0.000 description 8
229960004170 clozapine Drugs 0.000 description 7
QZUDBNBUXVUHMW-UHFFFAOYSA-N clozapine Chemical compound C1CN(C)CCN1C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12 QZUDBNBUXVUHMW-UHFFFAOYSA-N 0.000 description 7
230000037213 diet Effects 0.000 description 7
230000004584 weight gain Effects 0.000 description 7
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 6
229960003105 metformin Drugs 0.000 description 6
206010022489 Insulin Resistance Diseases 0.000 description 5
108010092277 Leptin Proteins 0.000 description 5
206010012601 diabetes mellitus Diseases 0.000 description 5
238000000034 method Methods 0.000 description 5
208000001072 type 2 diabetes mellitus Diseases 0.000 description 5
102000016267 Leptin Human genes 0.000 description 4
230000000259 anti-tumor effect Effects 0.000 description 4
230000006378 damage Effects 0.000 description 4
239000002552 dosage form Substances 0.000 description 4
235000013305 food Nutrition 0.000 description 4
229940039781 leptin Drugs 0.000 description 4
NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 description 4
229960004586 rosiglitazone Drugs 0.000 description 4
239000003981 vehicle Substances 0.000 description 4
208000032928 Dyslipidaemia Diseases 0.000 description 3
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
208000017170 Lipid metabolism disease Diseases 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
241000700159 Rattus Species 0.000 description 3
230000000561 anti-psychotic effect Effects 0.000 description 3
239000003795 chemical substances by application Substances 0.000 description 3
150000001875 compounds Chemical class 0.000 description 3
201000010099 disease Diseases 0.000 description 3
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
235000012631 food intake Nutrition 0.000 description 3
230000037406 food intake Effects 0.000 description 3
230000006698 induction Effects 0.000 description 3
239000000203 mixture Substances 0.000 description 3
231100000252 nontoxic Toxicity 0.000 description 3
230000003000 nontoxic effect Effects 0.000 description 3
235000016709 nutrition Nutrition 0.000 description 3
239000008399 tap water Substances 0.000 description 3
235000020679 tap water Nutrition 0.000 description 3
208000024172 Cardiovascular disease Diseases 0.000 description 2
108010010803 Gelatin Proteins 0.000 description 2
206010018429 Glucose tolerance impaired Diseases 0.000 description 2
208000001145 Metabolic Syndrome Diseases 0.000 description 2
241000699666 Mus <mouse, genus> Species 0.000 description 2
208000021642 Muscular disease Diseases 0.000 description 2
201000009623 Myopathy Diseases 0.000 description 2
238000011785 NMRI mouse Methods 0.000 description 2
241000700157 Rattus norvegicus Species 0.000 description 2
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
206010067584 Type 1 diabetes mellitus Diseases 0.000 description 2
201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 2
239000013543 active substance Substances 0.000 description 2
230000004075 alteration Effects 0.000 description 2
230000003178 anti-diabetic effect Effects 0.000 description 2
239000003472 antidiabetic agent Substances 0.000 description 2
239000002775 capsule Substances 0.000 description 2
230000008859 change Effects 0.000 description 2
230000001747 exhibiting effect Effects 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
229920000159 gelatin Polymers 0.000 description 2
239000008273 gelatin Substances 0.000 description 2
235000019322 gelatine Nutrition 0.000 description 2
235000011852 gelatine desserts Nutrition 0.000 description 2
229940088597 hormone Drugs 0.000 description 2
239000005556 hormone Substances 0.000 description 2
239000007788 liquid Substances 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
210000003470 mitochondria Anatomy 0.000 description 2
230000002438 mitochondrial effect Effects 0.000 description 2
230000004770 neurodegeneration Effects 0.000 description 2
208000015122 neurodegenerative disease Diseases 0.000 description 2
229940127017 oral antidiabetic Drugs 0.000 description 2
239000003755 preservative agent Substances 0.000 description 2
239000007787 solid Substances 0.000 description 2
239000008174 sterile solution Substances 0.000 description 2
230000003442 weekly effect Effects 0.000 description 2
ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 1
208000004611 Abdominal Obesity Diseases 0.000 description 1
201000004384 Alopecia Diseases 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
208000023275 Autoimmune disease Diseases 0.000 description 1
229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
208000031229 Cardiomyopathies Diseases 0.000 description 1
206010065941 Central obesity Diseases 0.000 description 1
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
208000023105 Huntington disease Diseases 0.000 description 1
206010020772 Hypertension Diseases 0.000 description 1
206010021518 Impaired gastric emptying Diseases 0.000 description 1
208000015580 Increased body weight Diseases 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
229930012538 Paclitaxel Natural products 0.000 description 1
208000018737 Parkinson disease Diseases 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
208000001280 Prediabetic State Diseases 0.000 description 1
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
208000036142 Viral infection Diseases 0.000 description 1
208000009621 actinic keratosis Diseases 0.000 description 1
230000003044 adaptive effect Effects 0.000 description 1
231100000360 alopecia Toxicity 0.000 description 1
206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 1
230000001548 androgenic effect Effects 0.000 description 1
229940125708 antidiabetic agent Drugs 0.000 description 1
239000003524 antilipemic agent Substances 0.000 description 1
239000000164 antipsychotic agent Substances 0.000 description 1
229940005529 antipsychotics Drugs 0.000 description 1
239000003443 antiviral agent Substances 0.000 description 1
VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
230000000903 blocking effect Effects 0.000 description 1
210000004204 blood vessel Anatomy 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
229910000389 calcium phosphate Inorganic materials 0.000 description 1
235000011010 calcium phosphates Nutrition 0.000 description 1
235000019577 caloric intake Nutrition 0.000 description 1
229960004562 carboplatin Drugs 0.000 description 1
239000001768 carboxy methyl cellulose Substances 0.000 description 1
235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
239000008112 carboxymethyl-cellulose Substances 0.000 description 1
239000000969 carrier Substances 0.000 description 1
210000004027 cell Anatomy 0.000 description 1
DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
229960004316 cisplatin Drugs 0.000 description 1
239000006071 cream Substances 0.000 description 1
230000007123 defense Effects 0.000 description 1
230000007812 deficiency Effects 0.000 description 1
230000002950 deficient Effects 0.000 description 1
201000009101 diabetic angiopathy Diseases 0.000 description 1
201000002249 diabetic peripheral angiopathy Diseases 0.000 description 1
230000000378 dietary effect Effects 0.000 description 1
208000016097 disease of metabolism Diseases 0.000 description 1
229960003668 docetaxel Drugs 0.000 description 1
229940079593 drug Drugs 0.000 description 1
239000003814 drug Substances 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
230000002500 effect on skin Effects 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
230000002124 endocrine Effects 0.000 description 1
230000019439 energy homeostasis Effects 0.000 description 1
239000000945 filler Substances 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
235000019634 flavors Nutrition 0.000 description 1
239000006260 foam Substances 0.000 description 1
210000000232 gallbladder Anatomy 0.000 description 1
208000001130 gallstones Diseases 0.000 description 1
208000021302 gastroesophageal reflux disease Diseases 0.000 description 1
208000001288 gastroparesis Diseases 0.000 description 1
102000054767 gene variant Human genes 0.000 description 1
230000002068 genetic effect Effects 0.000 description 1
239000008103 glucose Substances 0.000 description 1
235000001727 glucose Nutrition 0.000 description 1
230000002650 habitual effect Effects 0.000 description 1
230000036541 health Effects 0.000 description 1
235000009200 high fat diet Nutrition 0.000 description 1
230000000260 hypercholesteremic effect Effects 0.000 description 1
210000000936 intestine Anatomy 0.000 description 1
239000008101 lactose Substances 0.000 description 1
230000003902 lesion Effects 0.000 description 1
239000006210 lotion Substances 0.000 description 1
235000004213 low-fat Nutrition 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
230000003211 malignant effect Effects 0.000 description 1
230000006680 metabolic alteration Effects 0.000 description 1
230000004066 metabolic change Effects 0.000 description 1
208000030159 metabolic disease Diseases 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
230000037323 metabolic rate Effects 0.000 description 1
235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
239000003094 microcapsule Substances 0.000 description 1
150000007522 mineralic acids Chemical class 0.000 description 1
238000002156 mixing Methods 0.000 description 1
210000000214 mouth Anatomy 0.000 description 1
230000035772 mutation Effects 0.000 description 1
229960003512 nicotinic acid Drugs 0.000 description 1
239000011664 nicotinic acid Substances 0.000 description 1
239000003921 oil Substances 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
230000008520 organization Effects 0.000 description 1
201000008482 osteoarthritis Diseases 0.000 description 1
229960001756 oxaliplatin Drugs 0.000 description 1
DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 description 1
229960001592 paclitaxel Drugs 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
230000001575 pathological effect Effects 0.000 description 1
208000028169 periodontal disease Diseases 0.000 description 1
230000037081 physical activity Effects 0.000 description 1
230000035790 physiological processes and functions Effects 0.000 description 1
230000036470 plasma concentration Effects 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
239000000843 powder Substances 0.000 description 1
201000009104 prediabetes syndrome Diseases 0.000 description 1
230000008569 process Effects 0.000 description 1
229940083082 pyrimidine derivative acting on arteriolar smooth muscle Drugs 0.000 description 1
150000003230 pyrimidines Chemical class 0.000 description 1
230000005855 radiation Effects 0.000 description 1
231100000272 reduced body weight Toxicity 0.000 description 1
230000036186 satiety Effects 0.000 description 1
235000019627 satiety Nutrition 0.000 description 1
230000011664 signaling Effects 0.000 description 1
239000000377 silicon dioxide Substances 0.000 description 1
235000019333 sodium laurylsulphate Nutrition 0.000 description 1
239000000243 solution Substances 0.000 description 1
239000002904 solvent Substances 0.000 description 1
239000001593 sorbitan monooleate Substances 0.000 description 1
235000011069 sorbitan monooleate Nutrition 0.000 description 1
229940035049 sorbitan monooleate Drugs 0.000 description 1
239000000600 sorbitol Substances 0.000 description 1
239000007921 spray Substances 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
210000002784 stomach Anatomy 0.000 description 1
239000000126 substance Substances 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
239000000725 suspension Substances 0.000 description 1
239000003826 tablet Substances 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
229960001641 troglitazone Drugs 0.000 description 1
GXPHKUHSUJUWKP-UHFFFAOYSA-N troglitazone Chemical compound C1CC=2C(C)=C(O)C(C)=C(C)C=2OC1(C)COC(C=C1)=CC=C1CC1SC(=O)NC1=O GXPHKUHSUJUWKP-UHFFFAOYSA-N 0.000 description 1
GXPHKUHSUJUWKP-NTKDMRAZSA-N troglitazone Natural products C([C@@]1(OC=2C(C)=C(C(=C(C)C=2CC1)O)C)C)OC(C=C1)=CC=C1C[C@H]1SC(=O)NC1=O GXPHKUHSUJUWKP-NTKDMRAZSA-N 0.000 description 1
230000009385 viral infection Effects 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
230000004580 weight loss Effects 0.000 description 1
239000000080 wetting agent Substances 0.000 description 1

Landscapes

Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

ES07766498T 2006-11-02 2007-07-23 Reducción del sobrepeso o de la obesidad. Active ES2355680T3 (es)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date
US85611706P	2006-11-02	2006-11-02
US856117P		2006-11-02
US687945		2007-03-19

Publications (1)

Publication Number	Publication Date
ES2355680T3 true ES2355680T3 (es)	2011-03-30

Family

ID=41657988

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ES07766498T Active ES2355680T3 (es)	2006-11-02	2007-07-23	Reducción del sobrepeso o de la obesidad.

Country Status (4)

Country	Link
CN (1)	CN101646439B (uk)
ES (1)	ES2355680T3 (uk)
UA (1)	UA96312C2 (uk)
ZA (1)	ZA200902760B (uk)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1408966B1 (en) *	2001-07-17	2008-02-20	N-Gene Research Laboratories Inc.	Synergistic pharmaceutical combinations for the prevention or treatment of diabetes

2007
- 2007-07-23 ZA ZA200902760A patent/ZA200902760B/xx unknown
- 2007-07-23 ES ES07766498T patent/ES2355680T3/es active Active
- 2007-07-23 CN CN2007800405491A patent/CN101646439B/zh not_active Expired - Fee Related
- 2007-07-23 UA UAA200905422A patent/UA96312C2/uk unknown

Also Published As

Publication number	Publication date
ZA200902760B (en)	2010-06-30
CN101646439A (zh)	2010-02-10
CN101646439B (zh)	2011-09-07
UA96312C2 (uk)	2011-10-25

Publication	Publication Date	Title
US7737165B2 (en)	2010-06-15	Methods of reducing weight gain associated with olanzapine treatment
US7834056B2 (en)	2010-11-16	Pharmaceutical composition for gout
RU2443417C2 (ru)	2012-02-27	Уменьшение избыточной массы тела или ожирения
ES2778065T3 (es)	2020-08-07	Administración transmucosal de tocotrienol
ES2705726T3 (es)	2019-03-26	Métodos para tratar el aumento de peso inducido por antipsicóticos
US20200261392A1 (en)	2020-08-20	Method of treatment
WO2006094674A1 (en)	2006-09-14	Nmda receptor antagonists in the medical intervention of metabolic disorders
ES2206706T3 (es)	2004-05-16	Utilizacion de deshidro-epiandrosterona y de un agente inhibidor de la aromatasa para la preparacion de un medicamento destinado al tratamiento de un defecto relativo y absoluto de androgenos en un varon.
ES2355680T3 (es)	2011-03-30	Reducción del sobrepeso o de la obesidad.
US20090281143A1 (en)	2009-11-12	Dose Reduction of a Cannabinoid CB1 Receptor Antagonist in the Treatment of Overweight or Obesity
ES2532000T3 (es)	2015-03-23	Composición farmacéutica para el tratamiento de la dependencia del alcohol
JP7569492B2 (ja)	2024-10-18	抗精神病薬誘発性体重増加のミリコリラントによる治療方法
US20120053172A1 (en)	2012-03-01	Use of a combination of diazoxide and metformin for treating obesity or obesity related disorders
ES2299738T3 (es)	2008-06-01	Composicion farmaceutica que combina el tenatoprazol y un antagonista de los receptores h2 a la histamina.
HK1131737B (en)	2011-05-27	Reduction of overweight or obesity
WO2004110338A2 (en)	2004-12-23	Methods of treating obesity and related disorders using tellurium and selenium compounds
US20100234362A1 (en)	2010-09-16	Use of diazoxide for suppressing the plasma insulin level in a mammal
US20260083747A1 (en)	2026-03-26	Compositions and methods for supporting mitochondrial health
WO2025167857A1 (zh)	2025-08-14	用于增强或改善肌肉功能和/或提高运动表现和/或预防或缓解疲劳的方法和组合物
HK40076638A (en)	2023-02-17	Methods of treating antipsychotic-induced weight gain with miricorilant
US20090170900A1 (en)	2009-07-02	Dosing regimen for weight loss
JP2006089393A (ja)	2006-04-06	二成分混合薬剤